why choose us

First received: October 20, 2023

Clinical Trial: Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: SARS CoV 2 Infection

Study Type: INTERVENTIONAL


Official Title: Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX as Heterologous Booster for the Prevention of Coronavirus Disease 2019 (COVID-19) in Adolescents From 12 Years

Brief Summary: This is a Phase IIb, open-label, uncontrolled, multi-centre, non-inferiority clinical trial, to assess the safety and immunogenicity of BIMERVAX® as a heterologous booster dose in adolescents.In this study a total of 300 adolescents from 12 to less than 18 years will be enrolled and followed for 12 months.

Read more